Centerbridge Partners - Q4 2021 holdings

$1.75 Billion is the total value of Centerbridge Partners's 111 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .

 Value Shares↓ Weighting
THC  TENET HEALTHCARE CORP$181,591,000
+23.0%
2,222,9310.0%10.36%
-40.0%
RADI  RADIUS GLOBAL INFRASTRCTRE I$175,893,000
-1.4%
10,925,0000.0%10.03%
-51.9%
GOCO  GOHEALTH INC$154,188,000
-24.7%
40,682,9610.0%8.80%
-63.2%
GNK  GENCO SHIPPING & TRADING LTD$73,033,000
-20.5%
4,564,5830.0%4.17%
-61.2%
GTX  GARRETT MOTION INC$27,221,000
+9.0%
3,390,0000.0%1.55%
-46.8%
VTIQ  VECTOIQ ACQUISITION CORP II$18,993,000
+0.3%
1,950,0000.0%1.08%
-51.0%
AFAQ  AF ACQUISITION CORP$5,832,000
-0.2%
600,0000.0%0.33%
-51.2%
LCA  LANDCADIA HOLDINGS IV INC$4,865,000
-0.1%
500,0000.0%0.28%
-51.1%
BGSX  BUILD ACQUISITION CORP$4,374,000
+0.3%
450,0000.0%0.25%
-51.0%
PRPC  CC NEUBERGER PRINCIPAL HOLDN$3,952,000
+1.1%
400,0000.0%0.22%
-50.8%
CFVI  CF ACQUISITION CORP VI$1,625,000
+11.5%
150,0000.0%0.09%
-45.3%
CFIV  CF ACQUISITION CORP IV$1,597,000
+0.7%
163,0000.0%0.09%
-50.8%
AGCB  ALTIMETER GROWTH CORP 2$1,479,000
-0.3%
150,0000.0%0.08%
-51.4%
DHHC  DIAMONDHEAD HOLDINGS CORPcl a$974,000
+0.2%
100,0000.0%0.06%
-50.9%
COLI  COLICITY INC$975,000
-0.2%
100,0000.0%0.06%
-50.9%
CPTK  CROWN PROPTECH ACQUISITIONS$990,000
+1.5%
100,0000.0%0.06%
-50.9%
 RXR ACQUISITION CORP$975,000
+0.3%
100,0000.0%0.06%
-50.9%
SHAC  SCP & CO HEALTHCARE ACQUSTN$980,000
+0.7%
100,0000.0%0.06%
-50.9%
HIII  HUDSON EXECUTIVE INVES III$972,000
-0.1%
100,0000.0%0.06%
-51.8%
AAC  ARES ACQUISITION CORPORATION$487,0000.0%50,0000.0%0.03%
-50.9%
EQHA  EQ HEALTH ACQUISITION CORP$485,000
-0.6%
50,0000.0%0.03%
-50.9%
FACA  FIGURE ACQUISITION CORP I$490,000
-0.4%
50,0000.0%0.03%
-50.9%
PAQC  PROVIDENT ACQUISITION CORPcl a$372,000
+1.1%
37,7310.0%0.02%
-51.2%
VTIQW  VECTOIQ ACQUISITION CORP II*w exp 01/07/202$327,000
+8.6%
389,9990.0%0.02%
-45.7%
LCAHW  LANDCADIA HOLDINGS IV INC*w exp 03/29/202$126,000
+0.8%
125,0000.0%0.01%
-53.3%
AFAQW  AF ACQUISITION CORP*w exp 03/23/202$118,000
+5.4%
200,0000.0%0.01%
-46.2%
CFVIW  CF ACQUISITION CORP VI*w exp 02/18/202$98,000
+226.7%
37,5000.0%0.01%
+50.0%
BGSXWS  BUILD ACQUISITION CORP*w exp 03/15/202$104,000
+6.1%
149,9990.0%0.01%
-45.5%
PRPCWS  CC NEUBERGER PRINCIPAL HOLDN*w exp 99/99/999$87,000
+8.8%
80,0000.0%0.01%
-44.4%
NXUWS  NOVUS CAPITAL CORPORATION II*w exp 02/02/202$62,000
+14.8%
49,9990.0%0.00%
-33.3%
DUNEW  DUNE ACQUISITION CORP*w exp 10/29/202$73,000
-25.5%
149,9990.0%0.00%
-63.6%
CFIVW  CF ACQUISITION CORP IV*w exp 12/31/202$74,000
-14.0%
99,9990.0%0.00%
-60.0%
VIIAW  7GC & CO HOLDINGS INC*w exp 12/23/202$56,000
+3.7%
92,4990.0%0.00%
-50.0%
SPAQWS  SPARTAN ACQUISITION CORP III*w exp 02/04/202$54,000
+31.7%
37,4990.0%0.00%
-40.0%
BIOTW  BIOTECH ACQUISITION COMPANY*w exp 11/30/202$33,0000.0%50,0000.0%0.00%
-50.0%
PAQCW  PROVIDENT ACQUISITION CORP*w exp 01/08/202$40,000
-11.1%
74,9990.0%0.00%
-60.0%
DLCAW  DEEP LAKE CAPITAL ACQUSTN CO*w exp 01/04/202$37,000
-19.6%
60,0000.0%0.00%
-60.0%
SHACW  SCP & CO HEALTHCARE ACQUSTN*w exp 01/27/202$28,000
-3.4%
50,0000.0%0.00%
-33.3%
EQHAWS  EQ HEALTH ACQUISITION CORP*w exp 02/02/202$13,000
-7.1%
24,9990.0%0.00%
-50.0%
RXRAW  RXR ACQUISITION CORP*w exp 03/08/202$14,000
-6.7%
19,9990.0%0.00%
-50.0%
IIIIW  INSU ACQUISITION CORP III*w exp 12/31/202$20,000
-23.1%
33,3330.0%0.00%
-66.7%
HIIIW  HUDSON EXECUTIVE INVES III*w exp 02/22/202$16,000
-5.9%
19,9990.0%0.00%
-50.0%
HCCCW  HEALTHCARE CAPITAL CORP*w exp 12/31/202$24,000
-31.4%
50,0000.0%0.00%
-75.0%
CPTKWS  CROWN PROPTECH ACQUISITIONS*w exp 99/99/999$19,000
+5.6%
33,3330.0%0.00%
-50.0%
AACWS  ARES ACQUISITION CORPORATION*w exp 99/99/999$18,000
+5.9%
20,0000.0%0.00%
-50.0%
FCAXWS  FORTRESS CAPITAL ACQUISITION*w exp 99/99/999$23,000
-11.5%
29,9990.0%0.00%
-66.7%
DHHCW  DIAMONDHEAD HOLDINGS CORP*w exp 01/28/202$15,000
-6.2%
24,9990.0%0.00%
-50.0%
COLIW  COLICITY INC*w exp 02/24/202$15,000
-11.8%
19,9990.0%0.00%
-50.0%
About Centerbridge Partners

Centerbridge Partners is a private investment management firm that was founded in 2005 by Mark Gallogly and Jeffrey Aronson. The firm is headquartered in New York City and has additional offices in London and Hong Kong. Centerbridge Partners manages over $25 billion in assets across a range of investment strategies, including private equity, distressed debt, and real estate.

The firm has a strong leadership team, with Mark Gallogly serving as the CEO and Jeffrey Aronson as the Chairman and Chief Investment Officer. The COO is William Rahm, who oversees the firm's operations and infrastructure.

Centerbridge Partners has a reputation for being a highly disciplined and opportunistic investor, with a focus on identifying undervalued assets and unlocking value through operational improvements. The firm has a track record of successfully investing in a range of industries, including healthcare, energy, and financial services.

One notable investment made by Centerbridge Partners was its acquisition of Syncora Holdings, a financial guarantee insurance company, in 2013. The firm was able to turn around the struggling company by implementing operational improvements and strategic initiatives, ultimately leading to a successful exit.

Overall, Centerbridge Partners is a well-respected investment management firm with a strong leadership team and a proven track record of success.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GENCO SHIPPING & TRADING LTD26Q4 202218.0%
AMERICAN RENAL ASSOCS HLDGS19Q4 202034.8%
EXTENDED STAY AMER INC18Q4 202064.1%
AMBAC FINL GROUP INC17Q1 20184.8%
QUAD / GRAPHICS INC16Q4 20176.1%
IRSA INVERSIONES Y REP S A16Q3 20191.4%
ALLY FINL INC15Q4 201712.4%
WMIH CORP13Q3 20182.5%
CRESUD S A C I F Y A13Q4 20160.8%
ATLANTICA YIELD PLC12Q1 20199.0%

View Centerbridge Partners's complete holdings history.

Latest significant ownerships (13-D/G)
Centerbridge Partners Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
KV PHARMACEUTICAL CO /DE/March 03, 2011? ?

View Centerbridge Partners's complete significant-ownership history.

Latest filings
TypeFiled
40-APP/A2024-03-04
13F-HR2024-02-14
13F-HR2023-11-14
40-APP2023-10-16
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16

View Centerbridge Partners's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Centerbridge Partners's holdings